ClinicalTrials.gg
CompletedNCT01154218Updated Oct 24, 2011Results posted

Bioequivalence And Food Effect Study Comparing The Commercial Formulation Of Crizotinib To Its Clinical Study Formulations And Commercial Formulation With Or Without Food In Healthy Volunteers

A Phase 1 interventional study of crizotinib in Healthy, sponsored by Pfizer. Completed at 1 site in Belgium. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2011-10-24.

Sponsored by Pfizer · Phase 1 and Interventional

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
36
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

The purpose of this study is to demonstrate bioequivalence of the Commercial Image Capsule (CIC) relative to the Immediate Release Tablet (IRT) of crizotinib, bioequivalence of CIC relative to Powder in Capsule (PIC) of crizotinib, and lack of an effect of high fat meal on the pharmacokinetics (PK) of crizotinib when administered as CIC Formulation in healthy volunteers.

Read the detailed description

The purpose of this study is to demonstrate bioequivalence of the CIC relative to IRT and CIC relative to PIC, and lack of an effect of food on the PK of crizotinib in healthy volunteers.

02

Conditions studied

  • Healthy

Keywords

  • bioequivalence
  • food effect
  • pharmacokinetics
  • crizotinib
03

In context

Lead sponsor

Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.

Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy male and/or female of non- subjects between the ages of 18 and 55 years, inclusive (Healthy is defined as no abnormalities identified by a detailed medical history, full physical examination, including blood pressure and pulse rate measurement, 12-lead and clinical laboratory tests).
  • (BMI) of 17.5 to 30.5 kg/m\^2; and a total body weight >50 kg (110 lbs)

Exclusion criteria

Exclusion Criteria:

  • Subjects who are smoking, or with evidence of disease, conditions affecting absorption, treatment with other drug within 30 days, history of regular alcohol consumption, use of prescription, nonprescription drugs and dietary supplement within 7 days, or blood donation of 500 mL within 56 days.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
36 participants (actual)

Study arms

  • Experimental
    1

    All subjects will receive four treatments in one of the indicated orders: A-B-C-D, B-D-A-C, C-A-D-B, D-C-B-A

    Drug: crizotinib

Interventions

  • Treatment A (Reference 1): a 250 mg single dose of crizotinib administered in a fasted state as 1 × 50-mg IRT and 2 × 100-mg IRTs. Treatment B (Reference 2): a 250 mg single dose of crizotinib administered in a fasted state as 1 × 50-mg PIC and 2 × 100 mg PICs. Treatment C (Test for BE, Reference for Food Effect): a 250 mg single dose of crizotinib administered in a fasted state as 1 × 250-mg CIC. Treatment D (Test High Fat): a 250 mg single dose of crizotinib administered with a high-fat meal as 1 × 250-mg CIC

06

What researchers measure

Primary outcomes

  1. Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUC [0 - ∞])

    AUC (0-∞) = Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0-∞). It is obtained from AUC (0-t) plus AUC (t-∞).

    Time frame: 0 (pre-dose), 1, 2, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96 and 144 hours (hrs) post crizotinib dose

  2. Maximum Observed Plasma Concentration (Cmax)

    Time frame: 0 (pre-dose), 1, 2, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96 and 144 hrs post crizotinib dose

Secondary outcomes

  1. Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast)

    Area under the plasma concentration time-curve from zero (pre-dose) to the last measured concentration (AUClast).

    Time frame: 0 (pre-dose), 1, 2, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96 and 144 hrs post crizotinib dose

  2. Time to Reach Maximum Observed Plasma Concentration (Tmax)

    Time frame: 0 (pre-dose), 1, 2, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96 and 144 hrs post crizotinib dose

  3. Plasma Decay Half Life (t1/2)

    Plasma decay half-life is the time measured for the plasma concentration to decrease by one half.

    Time frame: 0 (pre-dose), 1, 2, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96 and 144 hrs post crizotinib dose

  4. Apparent Oral Clearance (CL/F)

    Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the body. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed.

    Time frame: 0 (pre-dose), 1, 2, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96 and 144 hrs post crizotinib dose

  5. Apparent Volume of Distribution (Vz/F)

    Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired blood concentration of a drug. Apparent volume of distribution after oral dose (Vz/F) is influenced by the fraction absorbed.

    Time frame: 0 (pre-dose), 1, 2, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96 and 144 hrs post crizotinib dose

  6. Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) for Crizotinib Metabolite (PF-06260182)

    Area under the plasma concentration time-curve from zero (pre-dose) to the last measured concentration (AUClast) of Crizotinib metabolite (PF-06260182).

    Time frame: 0 (pre-dose), 1, 2, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96 and 144 hrs post crizotinib dose

  7. Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUC [0 - ∞]) for Crizotinib Metabolite (PF-06260182)

    AUC (0-∞) = Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0-∞). It is obtained from AUC (0-t) plus AUC (t-∞).

    Time frame: 0 (pre-dose), 1, 2, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96 and 144 hrs post crizotinib dose

  8. Maximum Observed Plasma Concentration (Cmax) for Crizotinib Metabolite (PF-06260182)

    Time frame: 0 (pre-dose), 1, 2, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96 and 144 hrs post crizotinib dose

  9. Time to Reach Maximum Observed Plasma Concentration (Tmax) for Crizotinib Metabolite (PF-06260182)

    Time frame: 0 (pre-dose), 1, 2, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96 and 144 hrs post crizotinib dose

07

Results

Posted Oct 19, 2011

Participant flow

First Intervention Period
Participant flow — First Intervention Period
MilestoneCrizotinib 250 mg IRT Fasted, PIC Fasted, CIC Fasted, CIC FedCrizotinib 250 mg PIC Fasted, CIC Fed, IRT Fasted, CIC FastedCrizotinib 250 mg CIC Fasted, IRT Fasted, CIC Fed, PIC FastedCrizotinib 250 mg CIC Fed, CIC Fasted, PIC Fasted, IRT Fasted
Started9999
Completed9999
Not completed0000
Washout Period (at Least 14 Days)
Participant flow — Washout Period (at Least 14 Days)
MilestoneCrizotinib 250 mg IRT Fasted, PIC Fasted, CIC Fasted, CIC FedCrizotinib 250 mg PIC Fasted, CIC Fed, IRT Fasted, CIC FastedCrizotinib 250 mg CIC Fasted, IRT Fasted, CIC Fed, PIC FastedCrizotinib 250 mg CIC Fed, CIC Fasted, PIC Fasted, IRT Fasted
Started9999
Completed9999
Not completed0000
Second Intervention Period
Participant flow — Second Intervention Period
MilestoneCrizotinib 250 mg IRT Fasted, PIC Fasted, CIC Fasted, CIC FedCrizotinib 250 mg PIC Fasted, CIC Fed, IRT Fasted, CIC FastedCrizotinib 250 mg CIC Fasted, IRT Fasted, CIC Fed, PIC FastedCrizotinib 250 mg CIC Fed, CIC Fasted, PIC Fasted, IRT Fasted
Started9999
Completed9999
Not completed0000
Washout Period (at Least 14 Days)
Participant flow — Washout Period (at Least 14 Days)
MilestoneCrizotinib 250 mg IRT Fasted, PIC Fasted, CIC Fasted, CIC FedCrizotinib 250 mg PIC Fasted, CIC Fed, IRT Fasted, CIC FastedCrizotinib 250 mg CIC Fasted, IRT Fasted, CIC Fed, PIC FastedCrizotinib 250 mg CIC Fed, CIC Fasted, PIC Fasted, IRT Fasted
Started9999
Completed9999
Not completed0000
Third Intervention Period
Participant flow — Third Intervention Period
MilestoneCrizotinib 250 mg IRT Fasted, PIC Fasted, CIC Fasted, CIC FedCrizotinib 250 mg PIC Fasted, CIC Fed, IRT Fasted, CIC FastedCrizotinib 250 mg CIC Fasted, IRT Fasted, CIC Fed, PIC FastedCrizotinib 250 mg CIC Fed, CIC Fasted, PIC Fasted, IRT Fasted
Started9999
Completed9899
Not completed0100
Withdrew: Adverse event0100
Washout Period (at Least 14 Days)
Participant flow — Washout Period (at Least 14 Days)
MilestoneCrizotinib 250 mg IRT Fasted, PIC Fasted, CIC Fasted, CIC FedCrizotinib 250 mg PIC Fasted, CIC Fed, IRT Fasted, CIC FastedCrizotinib 250 mg CIC Fasted, IRT Fasted, CIC Fed, PIC FastedCrizotinib 250 mg CIC Fed, CIC Fasted, PIC Fasted, IRT Fasted
Started9899
Completed9898
Not completed0001
Withdrew: Withdrawal by subject0001
Fourth Intervention Period
Participant flow — Fourth Intervention Period
MilestoneCrizotinib 250 mg IRT Fasted, PIC Fasted, CIC Fasted, CIC FedCrizotinib 250 mg PIC Fasted, CIC Fed, IRT Fasted, CIC FastedCrizotinib 250 mg CIC Fasted, IRT Fasted, CIC Fed, PIC FastedCrizotinib 250 mg CIC Fed, CIC Fasted, PIC Fasted, IRT Fasted
Started9898
Completed8898
Not completed1000
Withdrew: Withdrawal by subject1000

Outcome measures

PrimaryArea Under the Curve From Time Zero to Extrapolated Infinite Time (AUC [0 - ∞])

AUC (0-∞) = Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0-∞). It is obtained from AUC (0-t) plus AUC (t-∞).

Time frame:
0 (pre-dose), 1, 2, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96 and 144 hours (hrs) post crizotinib dose
Reported as:
Geometric mean · ng*hr/mL
Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUC [0 - ∞])
ng*hr/mLCrizotinib IRT FastedCrizotinib PIC FastedCrizotinib CIC FastedCrizotinib CIC Fed
Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUC [0 - ∞])2890.0 ± 1021.82665.0 ± 1190.42887.0 ± 1109.62475.0 ± 1037.7
Statistical analysis
  • Crizotinib IRT Fasted vs Crizotinib CIC Fasted · Ratio of adjusted means: 99.56 · 90% CI 91.49 to 108.33
  • Crizotinib PIC Fasted vs Crizotinib CIC Fasted · Ratio of adjusted means: 106.93 · 90% CI 98.26 to 116.35
  • Crizotinib CIC Fasted vs Crizotinib CIC Fed · Ratio of adjusted means: 85.76 · 90% CI 78.88 to 93.25
SecondaryArea Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast)

Area under the plasma concentration time-curve from zero (pre-dose) to the last measured concentration (AUClast).

Time frame:
0 (pre-dose), 1, 2, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96 and 144 hrs post crizotinib dose
Reported as:
Geometric mean · ng*hr/mL
Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast)
ng*hr/mLCrizotinib IRT FastedCrizotinib PIC FastedCrizotinib CIC FastedCrizotinib CIC Fed
Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast)2763.0 ± 989.02531.0 ± 1158.02761.0 ± 1078.42359.0 ± 1013.0
Statistical analysis
  • Crizotinib IRT Fasted vs Crizotinib CIC Fasted · Ratio of adjusted means: 99.60 · 90% CI 91.30 to 108.66
  • Crizotinib PIC Fasted vs Crizotinib CIC Fasted · Ratio of adjusted means: 107.56 · 90% CI 98.58 to 117.35
  • Crizotinib CIC Fasted vs Crizotinib CIC Fed · Ratio of adjusted means: 85.52 · 90% CI 78.45 to 93.22
SecondaryTime to Reach Maximum Observed Plasma Concentration (Tmax)
Time frame:
0 (pre-dose), 1, 2, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96 and 144 hrs post crizotinib dose
Reported as:
Median · hr
Time to Reach Maximum Observed Plasma Concentration (Tmax)
hrCrizotinib IRT FastedCrizotinib PIC FastedCrizotinib CIC FastedCrizotinib CIC Fed
Time to Reach Maximum Observed Plasma Concentration (Tmax)5.00 (1.00 to 8.00)5.00 (2.00 to 6.00)5.00 (2.00 to 6.00)5.00 (1.00 to 8.00)
SecondaryPlasma Decay Half Life (t1/2)

Plasma decay half-life is the time measured for the plasma concentration to decrease by one half.

Time frame:
0 (pre-dose), 1, 2, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96 and 144 hrs post crizotinib dose
Reported as:
Mean · hr
Plasma Decay Half Life (t1/2)
hrCrizotinib IRT FastedCrizotinib PIC FastedCrizotinib CIC FastedCrizotinib CIC Fed
Plasma Decay Half Life (t1/2)34.62 ± 4.1335.28 ± 6.3934.85 ± 4.9435.41 ± 5.49
PrimaryMaximum Observed Plasma Concentration (Cmax)
Time frame:
0 (pre-dose), 1, 2, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96 and 144 hrs post crizotinib dose
Reported as:
Geometric mean · ng/mL
Maximum Observed Plasma Concentration (Cmax)
ng/mLCrizotinib IRT FastedCrizotinib PIC FastedCrizotinib CIC FastedCrizotinib CIC Fed
Maximum Observed Plasma Concentration (Cmax)126.00 ± 36.58119.30 ± 50.88135.00 ± 47.84116.10 ± 45.58
Statistical analysis
  • Crizotinib IRT Fasted vs Crizotinib CIC Fasted · Ratio of adjusted means: 106.97 · 90% CI 96.55 to 118.51
  • Crizotinib PIC Fasted vs Crizotinib CIC Fasted · Ratio of adjusted means: 111.32 · 90% CI 100.47 to 123.33
  • Crizotinib CIC Fasted vs Crizotinib CIC Fed · Ratio of adjusted means: 86.22 · 90% CI 77.89 to 95.43
SecondaryApparent Oral Clearance (CL/F)

Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the body. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed.

Time frame:
0 (pre-dose), 1, 2, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96 and 144 hrs post crizotinib dose
Reported as:
Geometric mean · L/hr
Apparent Oral Clearance (CL/F)
L/hrCrizotinib IRT FastedCrizotinib PIC FastedCrizotinib CIC FastedCrizotinib CIC Fed
Apparent Oral Clearance (CL/F)86.49 ± 30.4293.78 ± 49.8086.57 ± 53.63101.00 ± 38.60
SecondaryApparent Volume of Distribution (Vz/F)

Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired blood concentration of a drug. Apparent volume of distribution after oral dose (Vz/F) is influenced by the fraction absorbed.

Time frame:
0 (pre-dose), 1, 2, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96 and 144 hrs post crizotinib dose
Reported as:
Geometric mean · L
Apparent Volume of Distribution (Vz/F)
LCrizotinib IRT FastedCrizotinib PIC FastedCrizotinib CIC FastedCrizotinib CIC Fed
Apparent Volume of Distribution (Vz/F)4290.0 ± 1672.44703.0 ± 2874.74313.0 ± 3880.95096.0 ± 2302.0
SecondaryArea Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) for Crizotinib Metabolite (PF-06260182)

Area under the plasma concentration time-curve from zero (pre-dose) to the last measured concentration (AUClast) of Crizotinib metabolite (PF-06260182).

Time frame:
0 (pre-dose), 1, 2, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96 and 144 hrs post crizotinib dose
Reported as:
Geometric mean · ng*hr/mL
Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) for Crizotinib Metabolite (PF-06260182)
ng*hr/mLCrizotinib IRT FastedCrizotinib PIC FastedCrizotinib CIC FastedCrizotinib CIC Fed
Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) for Crizotinib Metabolite (PF-06260182)432.20 ± 219.76391.20 ± 255.12436.90 ± 246.34325.00 ± 192.81
Statistical analysis
  • Crizotinib IRT Fasted vs Crizotinib CIC Fasted · Ratio of adjusted means: 100.03 · 90% CI 90.16 to 110.97
  • Crizotinib PIC Fasted vs Crizotinib CIC Fasted · Ratio of adjusted means: 108.85 · 90% CI 98.11 to 120.77
  • Crizotinib CIC Fasted vs Crizotinib CIC Fed · Ratio of adjusted means: 74.87 · 90% CI 67.55 to 82.98
SecondaryArea Under the Curve From Time Zero to Extrapolated Infinite Time (AUC [0 - ∞]) for Crizotinib Metabolite (PF-06260182)

AUC (0-∞) = Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0-∞). It is obtained from AUC (0-t) plus AUC (t-∞).

Time frame:
0 (pre-dose), 1, 2, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96 and 144 hrs post crizotinib dose
Reported as:
Geometric mean · ng*hr/mL
Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUC [0 - ∞]) for Crizotinib Metabolite (PF-06260182)
ng*hr/mLCrizotinib IRT FastedCrizotinib PIC FastedCrizotinib CIC FastedCrizotinib CIC Fed
Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUC [0 - ∞]) for Crizotinib Metabolite (PF-06260182)442.00 ± 221.96402.10 ± 257.39447.10 ± 248.23341.80 ± 194.91
Statistical analysis
  • Crizotinib IRT Fasted vs Crizotinib CIC Fasted · Ratio of adjusted means: 100.08 · 90% CI 90.46 to 110.73
  • Crizotinib PIC Fasted vs Crizotinib CIC Fasted · Ratio of adjusted means: 108.47 · 90% CI 98.03 to 120.02
  • Crizotinib CIC Fasted vs Crizotinib CIC Fed · Ratio of adjusted means: 76.59 · 90% CI 69.23 to 84.74
SecondaryMaximum Observed Plasma Concentration (Cmax) for Crizotinib Metabolite (PF-06260182)
Time frame:
0 (pre-dose), 1, 2, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96 and 144 hrs post crizotinib dose
Reported as:
Geometric mean · ng/mL
Maximum Observed Plasma Concentration (Cmax) for Crizotinib Metabolite (PF-06260182)
ng/mLCrizotinib IRT FastedCrizotinib PIC FastedCrizotinib CIC FastedCrizotinib CIC Fed
Maximum Observed Plasma Concentration (Cmax) for Crizotinib Metabolite (PF-06260182)32.20 ± 12.4829.74 ± 15.1933.04 ± 12.1223.64 ± 10.85
Statistical analysis
  • Crizotinib IRT Fasted vs Crizotinib CIC Fasted · Ratio of adjusted means: 102.11 · 90% CI 92.84 to 112.31
  • Crizotinib PIC Fasted vs Crizotinib CIC Fasted · Ratio of adjusted means: 108.87 · 90% CI 98.98 to 119.75
  • Crizotinib CIC Fasted vs Crizotinib CIC Fed · Ratio of adjusted means: 71.94 · 90% CI 65.46 to 79.05
SecondaryTime to Reach Maximum Observed Plasma Concentration (Tmax) for Crizotinib Metabolite (PF-06260182)
Time frame:
0 (pre-dose), 1, 2, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96 and 144 hrs post crizotinib dose
Reported as:
Median · hr
Time to Reach Maximum Observed Plasma Concentration (Tmax) for Crizotinib Metabolite (PF-06260182)
hrCrizotinib IRT FastedCrizotinib PIC FastedCrizotinib CIC FastedCrizotinib CIC Fed
Time to Reach Maximum Observed Plasma Concentration (Tmax) for Crizotinib Metabolite (PF-06260182)6.00 (4.00 to 8.02)6.00 (4.00 to 8.00)5.00 (4.00 to 10.00)6.00 (2.00 to 10.00)

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Crizotinib IRT Fasted—0/36 (0%)21/36 (58.3%)
Crizotinib PIC Fasted—0/36 (0%)24/36 (66.7%)
Crizotinib CIC Fasted—0/36 (0%)20/36 (55.6%)
Crizotinib CIC Fed—0/36 (0%)21/36 (58.3%)
Most frequent other events
Showing 10 of 28
Most frequent other events
EventCrizotinib IRT FastedCrizotinib PIC FastedCrizotinib CIC FastedCrizotinib CIC Fed
DiarrhoeaGastrointestinal disorders9/3613/3613/3613/36
NauseaGastrointestinal disorders5/3610/362/365/36
FatigueGeneral disorders3/365/362/361/36
HeadacheNervous system disorders4/365/364/363/36
NasopharyngitisInfections and infestations2/363/360/361/36
SomnolenceNervous system disorders1/361/361/363/36
Abdominal painGastrointestinal disorders0/361/360/362/36
Abdominal pain upperGastrointestinal disorders2/361/361/361/36
Epigastric discomfortGastrointestinal disorders2/361/362/360/36
Gastrointestinal sounds abnormalGastrointestinal disorders1/360/361/362/36

Baseline characteristics

Age Continuous
Age Continuous(years)Entire Study Population
Mean38.9 ± 8.1
Sex: Female, Male
Sex: Female, Male(Participants)Entire Study Population
Female0
Male36
08

Study locations

1 site
  • Pfizer Investigational Site
    Bruxelles, B-1070, Belgium
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2010, a primary completion of Nov 2010 and a completion of Nov 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2011, 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 29, 2010
First posted
Jun 30, 2010
Start
Aug 2010
Primary completionActual
Nov 2010
CompletionActual
Nov 2010
Results first posted
Oct 19, 2011
Last update
Oct 24, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 24, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01154218
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Jun 30, 2010
Start date
Aug 2010
Primary completion
Nov 2010
Completion
Nov 2010
Results posted
Oct 19, 2011
Last update
Oct 24, 2011

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Crizotinib

Start the discussion